Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments

Advanced Drug Delivery Reviews

Volumn 69-70, Issue , 2014, Pages 170-178

  McGivern, Jered V ^a   Ebert, Allison D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cardiotoxicity; Disease modeling; Embryonic stem cells; Hepatotoxicity; High content screening; High throughput screening; Induced pluripotent stem cells

Indexed keywords

ACCIDENT PREVENTION; BIOCHEMISTRY; DIAGNOSIS; DRUG PRODUCTS;

CARDIOTOXICITY; DISEASE MODELING; EMBRYONIC STEM CELLS; HEPATOTOXICITY; HIGH THROUGHPUT SCREENING; HIGH-CONTENT SCREENING; INDUCED PLURIPOTENT STEM CELLS;

STEM CELLS;

BIOTECHNOLOGY; DISEASE MODEL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; TOXICOLOGY; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PLURIPOTENT STEM CELLS;

EID: 84899971912     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.11.012     Document Type: Review

References (138)

1. Eglen R., Reisine T. Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening. Assay Drug Dev. Technol. 2011, 9:108-124.
2. Santacruz-Toloza L., Huang Y., John S.A., Papazian D.M. Glycosylation of shaker potassium channel protein in insect cell culture and in Xenopus oocytes. Biochemistry 1994, 33:5607-5613.
3. Tang C.Y., Schulteis C.T., Jimenez R.M., Papazian D.M. Shaker and ether-a-go-go K+ channel subunits fail to coassemble in Xenopus oocytes. Biophys. J. 1998, 75:1263-1270.
4. Skarnes W.C., Rosen B., West A.P., Koutsourakis M., Bushell W., et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature 2011, 474:337-342.
5. Duyk G. Attrition and translation. Science 2003, 302:603-605.
6. Horrobin D.F. Modern biomedical research: an internally self-consistent universe with little contact with medical reality?. Nat. Rev. Drug Discov. 2003, 2:151-154.
7. Rajamohan D., Matsa E., Kalra S., Crutchley J., Patel A., et al. Current status of drug screening and disease modelling in human pluripotent stem cells. Bioessays 2013, 35:281-298.
8. Laustriat D., Gide J., Peschanski M. Human pluripotent stem cells in drug discovery and predictive toxicology. Biochem. Soc. Trans. 2010, 38:1051-1057.
9. Ho R.H., Tirona R.G., Leake B.F., Glaeser H., Lee W., et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006, 130:1793-1806.
10. Grover A., Benet L.Z. Effects of drug transporters on volume of distribution. AAPS J. 2009, 11:250-261.
11. Lai Y. Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion. Expert Opin. Drug Metab. Toxicol. 2009, 5:1175-1187.
12. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., et al. Properties of hERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J. 1998, 74:230-241.
13. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
14. Mattis V.B., Svendsen C.N. Induced pluripotent stem cells: a new revolution for clinical neurology?. Lancet Neurol. 2011, 10:383-394.
15. Knowles J., Gromo G. A guide to drug discovery: target selection in drug discovery. Nat. Rev. Drug Discov. 2003, 2:63-69.
16. Lindsay M.A. Target discovery. Nat. Rev. Drug Discov. 2003, 2:831-838.
17. Hermanson S.B., Carlson C.B., Riddle S.M., Zhao J., Vogel K.W., et al. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation. PLoS One 2012, 7:e43580.
18. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nat. Rev. Drug Discov. 2006, 5:993-996.
19. Vogel K.R., Pearl P.L., Theodore W.H., McCarter R.C., Jakobs C., et al. Thirty years beyond discovery-clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. J. Inherit. Metab. Dis. 2013, 36:401-410.
20. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat. Rev. Drug Discov. 2011, 10:328-329.
21. Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 2011, 10:87.
22. Swinney D.C., Anthony J. How were new medicines discovered?. Nat. Rev. Drug Discov. 2011, 10:507-519.
23. Giacomotto J., Ségalat L., Carre-Pierrat M., Gieseler K. Caenorhabditis elegans as a chemical screening tool for the study o f neuromuscular disorders. Manual and semi-automated methods. Methods 2012, 56:103-113.
24. Zheng W., Thorne N., McKew J.C. Phenotypic screens as a renewed approach for drug discovery. Drug Discov. Today 2013, 18:1067-1073.
25. Burkhardt M.F., Martinez F.J., Wright S., Ramos C., Volfson D., et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell. Neurosci. 2013, 56:355-364.
26. Feldkötter M., Schwarzer V., Wirth R., Wienker T.F., Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 2002, 70:358-368.
27. Ebert A.D., Yu J., Rose F.F., Mattis V.B., Lorson C.L., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
28. Sareen D., Ebert A.D., Heins B.M., McGivern J.V., Ornelas L., et al. Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS One 2012, 7:e39113.
29. McGivern J.V., Patitucci T.N., Nord J.A., Barabas M.E., Stucky C.L., et al. Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production. Glia 2013, 61:1418-1428.
30. Coovert D.D., Le T.T., McAndrew P.E., Strasswimmer J., Crawford T.O., et al. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 1997, 6:1205-1214.
31. Sakla M.S., Lorson C.L. Induction of full-length survival motor neuron by polyphenol botanical compounds. Hum. Genet. 2008, 122:635-643.
32. Young P.J., Le T.T., Dunckley M., Nguyen T.M., Burghes A.H., et al. Nuclear gems and Cajal (coiled) bodies in fetal tissues: nucleolar distribution of the spinal muscular atrophy protein, SMN. Exp. Cell Res. 2001, 265:252-261.
33. Xia X., Wong S.T. Concise review: a high-content screening approach to stem cell research and drug discovery. Stem Cells 2012, 30:1800-1807.
34. Liptrot C. High content screening-from cells to data to knowledge. Drug Discov. Today 2001, 6:832-834.
35. Macarron R., Banks M.N., Bojanic D., Burns D.J., Cirovic D.A., et al. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 2011, 10:188-195.
36. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
37. Chen S., Do J.T., Zhang Q., Yao S., Yan F., et al. Self-renewal of embryonic stem cells by a small molecule. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17266-17271.
38. Desbordes S.C., Placantonakis D.G., Ciro A., Socci N.D., Lee G., et al. High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell 2008, 2:602-612.
39. Damoiseaux R., Sherman S.P., Alva J.A., Peterson C., Pyle A.D. Integrated chemical genomics reveals modifiers of survival in human embryonic stem cells. Stem Cells 2009, 27:533-542.
40. Andrews P.D., Becroft M., Aspegren A., Gilmour J., James M.J., et al. High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. Biochem. J. 2010, 432:21-33.
41. Barbaric I., Jones M., Harley D.J., Gokhale P.J., Andrews P.W. High-content screening for chemical modulators of embryonal carcinoma cell differentiation and survival. J. Biomol. Screen. 2011, 16:603-617.
42. Desbordes S.C., Studer L. Adapting human pluripotent stem cells to high-throughput and high-content screening. Nat. Protoc. 2013, 8:111-130.
43. Borowiak M., Maehr R., Chen S., Chen A.E., Tang W., et al. Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell 2009, 4:348-358.
44. Zhu S., Wurdak H., Wang J., Lyssiotis C.A., Peters E.C., et al. A small molecule primes embryonic stem cells for differentiation. Cell Stem Cell 2009, 4:416-426.
45. Falk A., Karlsson T.E., Kurdija S., Frisen J., Zupicich J. High-throughput identification of genes promoting neuron formation and lineage choice in mouse embryonic stem cells. Stem Cells 2007, 25:1539-1545.
46. Shan J., Schwartz R.E., Ross N.T., Logan D.J., Thomas D., et al. Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat. Chem. Biol. 2013, 9:514-520.
47. Carlson C., Koonce C., Aoyama N., Einhorn S., Fiene S., et al. Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy. J. Biomol. Screen. 2013, 18:1203-1211.
48. Valentin J.P., Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J. Pharmacol. Toxicol. Methods 2008, 58:77-87.
49. Dykens J.A., Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 2007, 12:777-785.
50. Peng S., Lacerda A.E., Kirsch G.E., Brown A.M., Bruening-Wright A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J. Pharmacol. Toxicol. Methods 2010, 61:277-286.
51. Brown A.M., Rampe D. Drug-induced long QT syndrome: is hERG the root of all evil. Pharm. News 2000, 7:15-20.
52. Redfern W., Carlsson L., Davis A., Lynch W., Mackenzie I., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45.
53. Moss A.J., Kass R.S. Long QT syndrome: from channels to cardiac arrhythmias. J. Clin. Invest. 2005, 115:2018-2024.
54. Roden D.M., Lazzara R., Rosen M., Schwartz P.J., Towbin J., et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996, 94:1996-2012.
55. Roche M., Renauleaud C., Ballet V., Doubovetzky M., Guillon J.M. The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability. J. Pharmacol. Toxicol. Methods 2010, 61:238-250.
56. Oros A., Beekman J.D., Vos M.A. The canine model with chronic, complete atrio-ventricular block. Pharmacol. Ther. 2008, 119:168-178.
57. Varkevisser R., Wijers S.C., van der Heyden M.A., Beekman J.D., Meine M., et al. Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo. Heart Rhythm 2012, 9:1718-1726.
58. He J.Q., Ma Y., Lee Y., Thomson J.A., Kamp T.J. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ. Res. 2003, 93:32-39.
59. Mummery C., Ward-van Oostwaard D., Doevendans P., Spijker R., van den Brink S., et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003, 107:2733-2740.
60. Sartiani L., Bettiol E., Stillitano F., Mugelli A., Cerbai E., et al. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells 2007, 25:1136-1144.
61. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res. 2009, 104:e30-e41.
62. Sirenko O., Cromwell E.F., Crittenden C., Wignall J.A., Wright F.A., et al. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicol. Appl. Pharmacol. 2013, 273:500-507.
63. Harris K., Aylott M., Cui Y., Louttit J.B., McMahon N.C., et al. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol. Sci. 2013, 134:412-426.
64. Minger S.L. Developing technologies to unlock the therapeutic and research potential of human stem cells. N. Biotechnol. 2013, 30:378-380.
65. Hather C., Roquemore L., Thomas N. High-content analysis of a live multiplexed cytotoxicity study using CytivaTM Cardiomyocytes and IN Cell Analyzer 2000. Healthcare Life Sciences Newsletter-Discovery Matters 2011, 13. (http://gelifesciences.co.jp/newsletter/life_science_news/pdf/dm013_016.pdf).
66. Gai H., Nguyen D.M., Moon Y.J., Aguila J.R., Fink L.M., et al. Generation of murine hepatic lineage cells from induced pluripotent stem cells. Differentiation 2010, 79:171-181.
67. Iwamuro M., Komaki T., Kubota Y., Seita M., Kawamoto H., et al. Hepatic differentiation of mouse iPS cells in vitro. Cell Transplant. 2010, 19:841-847.
68. Liu H., Ye Z., Kim Y., Sharkis S., Jang Y.Y. Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology 2010, 51:1810-1819.
69. Song Z., Cai J., Liu Y., Zhao D., Yong J., et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res. 2009, 19:1233-1242.
70. Sullivan G.J., Hay D.C., Park I.H., Fletcher J., Hannoun Z., et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 2010, 51:329-335.
71. Takata A., Otsuka M., Kogiso T., Kojima K., Yoshikawa T., et al. Direct differentiation of hepatic cells from human induced pluripotent stem cells using a limited number of cytokines. Hepatol. Int. 2011, 5:890-898.
72. Rao M.S. Thinking outside the liver: induced pluripotent stem cells for hepatic applications. World J. Gastroenterol. 2013, 19:3385.
73. Medine C.N., Lucendo-Villarin B., Storck C., Wang F., Szkolnicka D., et al. Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl. Med. 2013, 2:505-509.
74. Palmer J.A., Poenitzsch A.M., Smith S.M., Conard K.R., West P.R., et al. Metabolic biomarkers of prenatal alcohol exposure in human embryonic stem cell-derived neural lineages. Alcohol. Clin. Exp. Res. 2012, 36:1314-1324.
75. Kleinstreuer N.C., Smith A.M., West P.R., Conard K.R., Fontaine B.R., et al. Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. Toxicol. Appl. Pharmacol. 2011, 257:111-121.
76. Cezar G.G., Quam J.A., Smith A.M., Rosa G.J.M., Piekarczyk M.S., et al. Identification of small molecules from human embryonic stem cells using metabolomics. Stem Cells Dev. 2007, 16:869-882.
77. Itzhaki I., Maizels L., Huber I., Zwi-Dantsis L., Caspi O., et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471:225-229.
78. Jung C.B., Moretti A., Mederos y Schnitzler M., Iop L., Storch U., et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol. Med. 2012, 4:180-191.
79. Stoelzle S., Haythornthwaite A., Kettenhofen R., Kolossov E., Bohlen H., et al. Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction. J. Biomol. Screen. 2011, 16:910-916.
80. Stoelzle S., Obergrussberger A., Bruggemann A., Haarmann C., George M., et al. State-of-the-art automated patch clamp devices: heat activation, action potentials, and high throughput in ion channel screening. Front. Pharmacol. 2011, 2:76.
81. Pugsley M.K., Authier S., Curtis M.J. Back to the future: safety pharmacology methods and models in 2013. J. Pharmacol. Toxicol. Methods 2013, 68:1-6.
82. Bellin M., Marchetto M.C., Gage F.H., Mummery C.L. Induced pluripotent stem cells: the new patient?. Nat. Rev. Mol. Cell Biol. 2012, 13:713-726.
83. Carvajal-Vergara X., Sevilla A., D'Souza S.L., Ang Y.S., Schaniel C., et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010, 465:808-812.
84. Sun N., Yazawa M., Liu J., Han L., Sanchez-Freire V., et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 2012, 4:130ra147.
85. Ito D., Okano H., Suzuki N. Accelerating progress in induced pluripotent stem cell research for neurological diseases. Ann. Neurol. 2012, 72:167-174.
86. Egawa N., Kitaoka S., Tsukita K., Naitoh M., Takahashi K., et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 2012, 4. (145ra104-145ra104).
87. Bilican B., Serio A., Barmada S.J., Nishimura A.L., Sullivan G.J., et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. 2012, 109:5803-5808.
88. Yang Y.M., Gupta S.K., Kim K.J., Powers B.E., Cerqueira A., et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 2013, 12:713-726.
89. Vosough M., Omidinia E., Kadivar M., Shokrgozar M.-A., Pournasr B., et al. Generation of functional hepatocyte-like cells from human pluripotent stem cells in a scalable suspension culture. Stem Cells Dev. 2013, 22:2693-2705.
90. Schulz T.C., Young H.Y., Agulnick A.D., Babin M.J., Baetge E.E., et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One 2012, 7:e37004.
91. Ebert A.D., Shelley B.C., Hurley A.M., Onorati M., Castiglioni V., et al. EZ spheres: a stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs. Stem Cell Res. 2013, 10:417-427.
92. Steiner D., Khaner H., Cohen M., Even-Ram S., Gil Y., et al. Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension. Nat. Biotechnol. 2010, 28:361-364.
93. Hu B.Y., Weick J.P., Yu J., Ma L.X., Zhang X.Q., et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4335-4340.
94. Marro S., Pang Zhiping P., Yang N., Tsai M.-C., Qu K., et al. Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. Cell Stem Cell 2011, 9:374-382.
95. Pang Z.P., Yang N., Vierbuchen T., Ostermeier A., Fuentes D.R., et al. Induction of human neuronal cells by defined transcription factors. Nature 2011, 476:220-223.
96. Zhang Y., Pak C., Han Y., Ahlenius H., Zhang Z., et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 2013, 78:785-798.
97. Son Esther Y., Ichida Justin K., Wainger Brian J., Toma Jeremy S., Rafuse Victor F., et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 2011, 9:205-218.
98. Wada R., Muraoka N., Inagawa K., Yamakawa H., Miyamoto K., et al. Induction of human cardiomyocyte-like cells from fibroblasts by defined factors. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:12667-12672.
99. Gundry R.L., Riordon D.R., Tarasova Y., Chuppa S., Bhattacharya S., et al. A cell surfaceome map for immunophenotyping and sorting pluripotent stem cells. Mol. Cell. Proteomics 2012, 11:303-316.
100. Lieu D.K., Fu J.D., Chiamvimonvat N., Tung K.C., McNerney G.P., et al. Mechanism-based facilitated maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Arrhythm. Electrophysiol. 2013, 6:191-201.
101. Johnson M.A., Weick J.P., Pearce R.A., Zhang S.C. Functional neural development from human embryonic stem cells: accelerated synaptic activity via astrocyte coculture. J. Neurosci. 2007, 27:3069-3077.
102. Zhang S.C., Wernig M., Duncan I.D., Brustle O., Thomson J.A. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 2001, 19:1129-1133.
103. Lian X., Zhang J., Azarin S.M., Zhu K., Hazeltine L.B., et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat. Protoc. 2013, 8:162-175.
104. Cai J., DeLaForest A., Fisher J., Urick A., Wagner T., et al. Protocol for Directed Differentiation of Human Pluripotent Stem Cells Toward a Hepatocyte Fate. StemBook [Internet] 2008, Harvard Stem Cell Institute, Cambridge (MA), Available from: http://wwwncbinlmnihgov/books/NBK133278/.
105. Samsdodd F. Target-based drug discovery: is something wrong?. Drug Discov. Today 2005, 10:139-147.
106. Neumann S., Huang W., Titus S., Krause G., Kleinau G., et al. Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12471-12476.
107. Neuberger T., Burton B., Clark H., Van Goor F. Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators. Methods Mol. Biol. 2011, 741:39-54.
108. Mattis V.B., Rai R., Wang J., Chang C.-W.T., Coady T., et al. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum. Genet. 2006, 120:589-601.
109. Yuan H., Myers S., Wang J., Zhou D., Woo J.A., et al. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N. Engl. J. Med. 2012, 367:1220-1227.
110. Fulcher M.L., Gabriel S.E., Olsen J.C., Tatreau J.R., Gentzsch M., et al. Novel human bronchial epithelial cell lines for cystic fibrosis research. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296:L82-L91.
111. Titus S.A., Southall N., Marugan J., Austin C.P., Zheng W. High-throughput multiplexed quantitation of protein aggregation and cytotoxicity in a Huntington's disease model. Curr. Chem. Genomics 2012, 6:79-86.
112. Xiao J., Marugan J.J., Zheng W., Titus S., Southall N., et al. Discovery, synthesis, and biological evaluation of novel SMN protein modulators. J. Med. Chem. 2011, 54:6215-6233.
113. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 2010, 363:1397-1409.
114. Lahti A.L., Kujala V.J., Chapman H., Koivisto A.P., Pekkanen-Mattila M., et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis. Model. Mech. 2012, 5:220-230.
115. Matsa E., Rajamohan D., Dick E., Young L., Mellor I., et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur. Heart J. 2011, 32:952-962.
116. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
117. Dick E., Matsa E., Bispham J., Reza M., Guglieri M., et al. Two new protocols to enhance the production and isolation of human induced pluripotent stem cell lines. Stem Cell Res. 2011, 6:158-167.
118. Kazuki Y., Hiratsuka M., Takiguchi M., Osaki M., Kajitani N., et al. Complete genetic correction of iPS cells from Duchenne muscular dystrophy. Mol. Ther. 2010, 18:386-393.
119. Dick E., Kalra S., Anderson D., George V., Ritso M., et al. Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations. Stem Cells Dev. 2013, 22:2714-2724.
120. Song B., Sun G., Herszfeld D., Sylvain A., Campanale N.V., et al. Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis. Stem Cell Res. 2012, 8:259-273.
121. Chang T., Zheng W., Tsark W., Bates S., Huang H., et al. Brief report: phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. Stem Cells 2011, 29:2090-2093.
122. Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
123. Chiang C.H., Su Y., Wen Z., Yoritomo N., Ross C.A., et al. Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Mol. Psychiatry 2011, 16:358-360.
124. Yagi T., Ito D., Okada Y., Akamatsu W., Nihei Y., et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 2011, 20:4530-4539.
125. Yahata N., Asai M., Kitaoka S., Takahashi K., Asaka I., et al. Anti-Abeta drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One 2011, 6:e25788.
126. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136:964-977.
127. Sanchez-Danes A., Richaud-Patin Y., Carballo-Carbajal I., Jimenez-Delgado S., Caig C., et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med. 2012, 4:380-395.
128. Seibler P., Graziotto J., Jeong H., Simunovic F., Klein C., et al. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J. Neurosci. 2011, 31:5970-5976.
129. Hd C. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 2012, 11:264-278.
130. Zhang N., An M.C., Montoro D., Ellerby L.M. Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr. 2010, 2:RRN1193.
131. DeRosa B.A., Van Baaren J.M., Dubey G.K., Lee J.M., Cuccaro M.L., et al. Derivation of autism spectrum disorder-specific induced pluripotent stem cells from peripheral blood mononuclear cells. Neurosci. Lett. 2012, 516:9-14.
132. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
133. Mitne-Neto M., Machado-Costa M., Marchetto M.C., Bengtson M.H., Joazeiro C.A., et al. Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum. Mol. Genet. 2011, 20:3642-3652.
134. Maehr R., Chen S., Snitow M., Ludwig T., Yagasaki L., et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15768-15773.
135. Ohmine S., Squillace K.A., Hartjes K.A., Deeds M.C., Armstrong A.S., et al. Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency. Aging (Albany NY) 2012, 4:60-73.
136. Sebastiano V., Maeder M.L., Angstman J.F., Haddad B., Khayter C., et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 2011, 29:1717-1726.
137. Zou J., Mali P., Huang X., Dowey S.N., Cheng L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011, 118:4599-4608.
138. Jin Z.B., Okamoto S., Xiang P., Takahashi M. Integration-free induced pluripotent stem cells derived from retinitis pigmentosa patient for disease modeling. Stem Cells Transl. Med. 2012, 1:503-509.